Gain Therapeutics, Inc.’s GANX share price has surged by 13.74%, which has investors questioning if this is right time to sell.

and followed with two other licensing deals involving a pair of gene therapies for GM1 and GM2 gangliosidosis – AXO-AAV-GM1 and AXO-AAV-GM2 – from the University of Massachusetts. It also ...

The Brazilian project will focus on six programmes, targeting GM1 gangliosidosis (GM1), Krabbe disease, metachromatic leukodystrophy (MLD), and three unnamed programmes. The funding will be used ...

After hours: March 17 at 7:47:38 PM EDT Loading Chart for GANX ...